Chapter title |
Quantification of Tau Load in Alzheimer’s Disease Clinical Trials Using Positron Emission Tomography
|
---|---|
Chapter number | 15 |
Book title |
Biomarkers for Alzheimer’s Disease Drug Development
|
Published in |
Methods in molecular biology, January 2018
|
DOI | 10.1007/978-1-4939-7704-8_15 |
Pubmed ID | |
Book ISBNs |
978-1-4939-7703-1, 978-1-4939-7704-8
|
Authors |
Tessa Timmers, Bart N. M. van Berckel, Adriaan A. Lammertsma, Rik Ossenkoppele |
Abstract |
Alzheimer's disease is a neurodegenerative condition that is neuropathologically characterized by the presence of amyloid-β plaques and neurofibrillary tangles consisting of tau. Recently, several positron emission tomography (PET) tracers have been developed that yielded promising initial results. In this chapter, we discuss how tau PET can be used in the context in clinical trials. We argue that simplified reference tissue models based on dynamic data acquisition are most suitable for accurately measuring changes in tau pathology in trials tailored to reduce cerebral tau load. Therefore, we discuss the importance of tracer kinetic modeling and describe in detail how a reliable measurement of specific binding can be obtained. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 18 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 5 | 28% |
Student > Ph. D. Student | 3 | 17% |
Other | 2 | 11% |
Lecturer | 1 | 6% |
Student > Master | 1 | 6% |
Other | 1 | 6% |
Unknown | 5 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Neuroscience | 4 | 22% |
Medicine and Dentistry | 3 | 17% |
Psychology | 2 | 11% |
Computer Science | 1 | 6% |
Unknown | 8 | 44% |